Published in J Mol Biol on September 09, 2005
PharmMapper server: a web server for potential drug target identification using pharmacophore mapping approach. Nucleic Acids Res (2010) 1.50
Two CES1 gene mutations lead to dysfunctional carboxylesterase 1 activity in man: clinical significance and molecular basis. Am J Hum Genet (2008) 1.50
Multisite promiscuity in the processing of endogenous substrates by human carboxylesterase 1. J Mol Biol (2006) 1.42
Recommended nomenclature for five mammalian carboxylesterase gene families: human, mouse, and rat genes and proteins. Mamm Genome (2010) 1.40
Crystal structures of human carboxylesterase 1 in covalent complexes with the chemical warfare agents soman and tabun. Biochemistry (2007) 1.20
The functional G143E variant of carboxylesterase 1 is associated with increased clopidogrel active metabolite levels and greater clopidogrel response. Pharmacogenet Genomics (2013) 1.19
Carboxylesterase inhibitors. Expert Opin Ther Pat (2011) 1.06
Examination of the carboxylesterase phenotype in human liver. Arch Biochem Biophys (2012) 1.01
Biochemical and molecular analysis of carboxylesterase-mediated hydrolysis of cocaine and heroin. Br J Pharmacol (2010) 1.00
Analysis of mammalian carboxylesterase inhibition by trifluoromethylketone-containing compounds. Mol Pharmacol (2006) 0.99
Liver prenylated methylated protein methyl esterase is the same enzyme as Sus scrofa carboxylesterase. J Biochem Mol Toxicol (2008) 0.93
iDrug: a web-accessible and interactive drug discovery and design platform. J Cheminform (2014) 0.90
Mammalian carboxylesterase 5: comparative biochemistry and genomics. Comp Biochem Physiol Part D Genomics Proteomics (2008) 0.85
Polyisoprenylation potentiates the inhibition of polyisoprenylated methylated protein methyl esterase and the cell degenerative effects of sulfonyl fluorides. Curr Cancer Drug Targets (2011) 0.85
Mammalian carboxylesterase 3: comparative genomics and proteomics. Genetica (2010) 0.84
Opossum carboxylesterases: sequences, phylogeny and evidence for CES gene duplication events predating the marsupial-eutherian common ancestor. BMC Evol Biol (2008) 0.83
Requirements for mammalian carboxylesterase inhibition by substituted ethane-1,2-diones. Bioorg Med Chem (2011) 0.83
Biochemical and docking analysis of substrate interactions with polyisoprenylated methylated protein methyl esterase. Curr Cancer Drug Targets (2010) 0.83
Crystal structure of the Geobacillus stearothermophilus carboxylesterase Est55 and its activation of prodrug CPT-11. J Mol Biol (2006) 0.82
Baboon carboxylesterases 1 and 2: sequences, structures and phylogenetic relationships with human and other primate carboxylesterases. J Med Primatol (2009) 0.82
A new class of mammalian carboxylesterase CES6. Comp Biochem Physiol Part D Genomics Proteomics (2009) 0.80
Comparison of benzil and trifluoromethyl ketone (TFK)-mediated carboxylesterase inhibition using classical and 3D-quantitative structure-activity relationship analysis. Bioorg Med Chem (2008) 0.80
Influence of sulfur oxidation state and steric bulk upon trifluoromethyl ketone (TFK) binding kinetics to carboxylesterases and fatty acid amide hydrolase (FAAH). Bioorg Med Chem (2007) 0.80
Structural characterization and function determination of a nonspecific carboxylate esterase from the amidohydrolase superfamily with a promiscuous ability to hydrolyze methylphosphonate esters. Biochemistry (2014) 0.77
Bovine Carboxylesterases: Evidence for Two CES1 and Five Families of CES Genes on Chromosome 18. Comp Biochem Physiol Part D Genomics Proteomics (2009) 0.77
Molecular and functional characterization of cDNAs putatively encoding carboxylesterases from the migratory locust, Locusta migratoria. PLoS One (2014) 0.77
Horse carboxylesterases: evidence for six CES1 and four families of CES genes on chromosome 3. Comp Biochem Physiol Part D Genomics Proteomics (2008) 0.77
Substrate-Competitive Activity-Based Profiling of Ester Prodrug Activating Enzymes. Mol Pharm (2015) 0.77
Carboxylesterases: General detoxifying enzymes. Chem Biol Interact (2016) 0.77
Carboxylesterase 1 Is Regulated by Hepatocyte Nuclear Factor 4α and Protects Against Alcohol- and MCD diet-induced Liver Injury. Sci Rep (2016) 0.76
In Silico Design and Evaluation of Carboxylesterase Inhibitors. J Pest Sci (2004) (2010) 0.75
Comparison of the Structure and Activity of Glycosylated and Aglycosylated Human Carboxylesterase 1. PLoS One (2015) 0.75
Reactivity versus steric effects in fluorinated ketones as esterase inhibitors: a quantum mechanical and molecular dynamics study. J Mol Model (2010) 0.75
Immobilization of active human carboxylesterase 1 in biomimetic silica nanoparticles. Biotechnol Prog (2011) 0.75
Residue-centric modeling and design of saccharide and glycoconjugate structures. J Comput Chem (2016) 0.75
Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med (2011) 11.01
The pediatric preclinical testing program: description of models and early testing results. Pediatr Blood Cancer (2007) 5.28
TAZ promotes cell proliferation and epithelial-mesenchymal transition and is inhibited by the hippo pathway. Mol Cell Biol (2008) 5.02
Crystal structure of an ancient protein: evolution by conformational epistasis. Science (2007) 3.56
Initial testing of the aurora kinase A inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP). Pediatr Blood Cancer (2010) 2.99
Alleviating cancer drug toxicity by inhibiting a bacterial enzyme. Science (2010) 2.99
Long-term safety and efficacy of factor IX gene therapy in hemophilia B. N Engl J Med (2014) 2.92
Medulloblastoma: clinicopathological correlates of SHH, WNT, and non-SHH/WNT molecular subgroups. Acta Neuropathol (2011) 2.82
YAP1 is amplified and up-regulated in hedgehog-associated medulloblastomas and mediates Sonic hedgehog-driven neural precursor proliferation. Genes Dev (2009) 2.58
Structural and evolutionary division of phosphotyrosine binding (PTB) domains. J Mol Biol (2005) 2.19
CDK inhibitor p18(INK4c) is a downstream target of GATA3 and restrains mammary luminal progenitor cell proliferation and tumorigenesis. Cancer Cell (2009) 2.17
Crystal structure of human carboxylesterase 1 complexed with the Alzheimer's drug tacrine: from binding promiscuity to selective inhibition. Chem Biol (2003) 2.05
Modulation of human nuclear receptor LRH-1 activity by phospholipids and SHP. Nat Struct Mol Biol (2005) 2.03
The effect of combined antihypertensive treatment (felodipine with either irbesartan or metoprolol) on erectile function: a randomized controlled trial. Cardiology (2013) 2.02
Initial testing (stage 1) of the proteasome inhibitor bortezomib by the pediatric preclinical testing program. Pediatr Blood Cancer (2008) 1.95
Regulation of cyp3a gene transcription by the pregnane x receptor. Annu Rev Pharmacol Toxicol (2002) 1.87
Molecular characterization of the pediatric preclinical testing panel. Clin Cancer Res (2008) 1.84
Proteomic identification of the cerebral cavernous malformation signaling complex. J Proteome Res (2007) 1.83
Functional anatomy of phospholipid binding and regulation of phosphoinositide homeostasis by proteins of the sec14 superfamily. Mol Cell (2008) 1.82
The insulin-like growth factor-1 receptor-targeting antibody, CP-751,871, suppresses tumor-derived VEGF and synergizes with rapamycin in models of childhood sarcoma. Cancer Res (2009) 1.79
Sudemycins, novel small molecule analogues of FR901464, induce alternative gene splicing. ACS Chem Biol (2011) 1.77
Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF-1 receptor by the pediatric preclinical testing program. Pediatr Blood Cancer (2008) 1.71
Initial testing of topotecan by the pediatric preclinical testing program. Pediatr Blood Cancer (2010) 1.66
Mammalian carboxylesterases: from drug targets to protein therapeutics. Drug Discov Today (2005) 1.61
Coactivator binding promotes the specific interaction between ligand and the pregnane X receptor. J Mol Biol (2003) 1.57
Retracted Postconditioning promotes the cardiac repair through balancing collagen degradation and synthesis after myocardial infarction in rats. Basic Res Cardiol (2012) 1.57
Structural disorder in the complex of human pregnane X receptor and the macrolide antibiotic rifampicin. Mol Endocrinol (2005) 1.55
Initial testing (stage 1) of the mTOR inhibitor rapamycin by the pediatric preclinical testing program. Pediatr Blood Cancer (2008) 1.55
2.1 A crystal structure of human PXR in complex with the St. John's wort compound hyperforin. Biochemistry (2003) 1.55
Rho kinase inhibition rescues the endothelial cell cerebral cavernous malformation phenotype. J Biol Chem (2010) 1.51
Effect of felodipine with irbesartan or metoprolol on sexual function and oxidative stress in women with essential hypertension. J Hypertens (2012) 1.47
National Cancer Institute pediatric preclinical testing program: model description for in vitro cytotoxicity testing. Pediatr Blood Cancer (2010) 1.47
Development of a tumor-selective approach to treat metastatic cancer. PLoS One (2006) 1.46
Mechanisms of camptothecin resistance by human topoisomerase I mutations. J Mol Biol (2004) 1.46
Structural basis of heroin and cocaine metabolism by a promiscuous human drug-processing enzyme. Nat Struct Biol (2003) 1.46
Ischemia-modified albumin in patients with hyperthyroidism and hypothyroidism. Eur J Intern Med (2012) 1.45
Multisite promiscuity in the processing of endogenous substrates by human carboxylesterase 1. J Mol Biol (2006) 1.42
Identification of N10-substituted phenoxazines as potent and specific inhibitors of Akt signaling. J Biol Chem (2005) 1.41
Recommended nomenclature for five mammalian carboxylesterase gene families: human, mouse, and rat genes and proteins. Mamm Genome (2010) 1.40
Tumor-targeted enzyme/prodrug therapy mediates long-term disease-free survival of mice bearing disseminated neuroblastoma. Cancer Res (2007) 1.38
Therapeutic levels of FVIII following a single peripheral vein administration of rAAV vector encoding a novel human factor VIII variant. Blood (2013) 1.36
Crystal structure of the cofactor-binding domain of the human phase II drug-metabolism enzyme UDP-glucuronosyltransferase 2B7. J Mol Biol (2007) 1.35
Plasma and cerebrospinal fluid pharmacokinetics of erlotinib and its active metabolite OSI-420. Clin Cancer Res (2007) 1.35
Stage 2 combination testing of rapamycin with cytotoxic agents by the Pediatric Preclinical Testing Program. Mol Cancer Ther (2010) 1.34
Identification and characterization of novel benzil (diphenylethane-1,2-dione) analogues as inhibitors of mammalian carboxylesterases. J Med Chem (2005) 1.33
Disrupting antibiotic resistance propagation by inhibiting the conjugative DNA relaxase. Proc Natl Acad Sci U S A (2007) 1.32
Efficacy and pharmacokinetic/pharmacodynamic evaluation of the Aurora kinase A inhibitor MLN8237 against preclinical models of pediatric cancer. Cancer Chemother Pharmacol (2011) 1.30
Abnormal neural activity in the patients with remitted geriatric depression: a resting-state functional magnetic resonance imaging study. J Affect Disord (2008) 1.29
Orphan nuclear receptors adopted by crystallography. Curr Opin Struct Biol (2005) 1.28
Selective inhibition of carboxylesterases by isatins, indole-2,3-diones. J Med Chem (2007) 1.28
Initial testing (stage 1) of the BH3 mimetic ABT-263 by the pediatric preclinical testing program. Pediatr Blood Cancer (2008) 1.26
Crystal structure of the pregnane X receptor-estradiol complex provides insights into endobiotic recognition. Mol Endocrinol (2007) 1.25
Initial testing of the VEGFR inhibitor AZD2171 by the pediatric preclinical testing program. Pediatr Blood Cancer (2008) 1.25
Structural insights into CPT-11 activation by mammalian carboxylesterases. Nat Struct Biol (2002) 1.25
Initial testing of a monoclonal antibody (IMC-A12) against IGF-1R by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer (2010) 1.24
SK-NEP-1 and Rh1 are Ewing family tumor lines. Pediatr Blood Cancer (2008) 1.23
Gefitinib modulates the function of multiple ATP-binding cassette transporters in vivo. Cancer Res (2006) 1.23
Hydrolytic metabolism of pyrethroids by human and other mammalian carboxylesterases. Biochem Pharmacol (2006) 1.22
The role of proinflammatory cytokines in lung ischemia-reperfusion injury. J Thorac Cardiovasc Surg (2003) 1.21
Crystal structures of human carboxylesterase 1 in covalent complexes with the chemical warfare agents soman and tabun. Biochemistry (2007) 1.20
Initial testing (stage 1) of sunitinib by the pediatric preclinical testing program. Pediatr Blood Cancer (2008) 1.20
Molecular basis for pH-dependent mucosal dehydration in cystic fibrosis airways. Proc Natl Acad Sci U S A (2013) 1.20
Characterization of the N-acetyl-α-D-glucosaminyl l-malate synthase and deacetylase functions for bacillithiol biosynthesis in Bacillus anthracis . Biochemistry (2010) 1.20
Crystal structure of the PXR-T1317 complex provides a scaffold to examine the potential for receptor antagonism. Bioorg Med Chem (2006) 1.19
A minimal exonuclease domain of WRN forms a hexamer on DNA and possesses both 3'- 5' exonuclease and 5'-protruding strand endonuclease activities. Biochemistry (2002) 1.19
Planarity and constraint of the carbonyl groups in 1,2-diones are determinants for selective inhibition of human carboxylesterase 1. J Med Chem (2007) 1.18
Discovery of novel selective inhibitors of human intestinal carboxylesterase for the amelioration of irinotecan-induced diarrhea: synthesis, quantitative structure-activity relationship analysis, and biological activity. Mol Pharmacol (2004) 1.18
Dexamethasone increases expression and activity of multidrug resistance transporters at the rat blood-brain barrier. Am J Physiol Cell Physiol (2008) 1.16
Simvastatin ameliorates injury in an experimental model of lung ischemia-reperfusion. J Thorac Cardiovasc Surg (2003) 1.16